Dr. Chris Winter explores deprescribing — the clinical movement around when and how to stop medications — and examines why some 'forever drugs' like blood pressure medication are culturally accepted while others, such as antidepressants and GLP-1 agonists, are moralized and stigmatized. He contrasts the evidence on antidepressant tapering, GLP-1 safety data, and the RLS story where dopamine agonists were downgraded by 2025 AASM guidelines due to drug-induced worsening of symptoms. The episode also notes the quiet cultural acceptance of hypersomnia medications as a revealing exception, and questions what actually determines whether long-term medication is seen as managing chronic disease or a personal failing.
This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.
Highlights
•
The Cultural Double Standard Around 'Forever Drugs'
Blood pressure medication taken for life is accepted without question, but saying the same about an antidepressant or a GLP-1 agonist triggers moral judgment and stigma.
Two 2024 JAMA Internal Medicine studies found no elevated risk of depression or suicidality with GLP-1 agonists, yet the public discourse continues to treat these medications as morally suspect.
RLS Dopamine Agonists and the Augmentation Problem
The 2025 AASM guidelines downgraded dopamine agonists for restless legs syndrome after mounting evidence of augmentation — where the drug itself progressively worsens the symptoms it was meant to treat.
Medications for hypersomnia disorders generate almost no cultural friction, in striking contrast to the moralized debates around antidepressants, GLP-1s, and RLS treatments.
Deprescribing is a fast-growing clinical practice focused on the structured, evidence-based process of reducing or stopping medications when they may no longer be beneficial or may be causing harm.